CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 68 enrolled
Drug / intervention
Bevacizumab +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01399190
NCT01399190N/ACompleted
CompareCT.gov

An Open Label Study of the Effect of First Line Treatment With Bevacizumab in Combination With Capecitabine and Oxaliplatin on Progression-free Survival in Patients With Metastatic Cancer of the Colon and Rectum

Hoffmann-La Roche·observational·Posted Jul 21, 2011·Updated Sep 28, 2016

In Brief

An observational study evaluating Bevacizumab, Capecitabine, and 1 other intervention for Colorectal Cancer. Completed, enrolled 68 participants across 9 sites.

Detailed Summary

This prospective observational study will evaluate the efficacy and safety of bevacizumab in combination with capecitabine and oxaliplatin as first-line treatment in participants with colorectal cancer. Data will be collected from each participant until disease progression occurs (for up to 30 months).

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsColorectal Cancer
CountriesSlovakia
Collaborators--

Timeline

N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJul 21, 2011
Enrollment StartJul 1, 2011
Primary CompletionFeb 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 14.9 years ago

Interventions

Bevacizumabbiological

Bevacizumab administered according to prescribing information and normal clinical practice.

Capecitabinebiological

Capecitabine administered according to prescribing information and normal clinical practice.

Oxaliplatindrug

Capecitabine administered according to prescribing information and normal clinical practice.